Hidemi Mochizuki
Overview
Explore the profile of Hidemi Mochizuki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chinsuwan T, Hirabayashi K, Mishima S, Hasegawa A, Tanaka M, Mochizuki H, et al.
Mol Ther Oncolytics
. 2023 Oct;
31:100735.
PMID: 37860015
[This corrects the article DOI: 10.1016/j.omto.2023.100728.].
2.
Chinsuwan T, Hirabayashi K, Mishima S, Hasegawa A, Tanaka M, Mochizuki H, et al.
Mol Ther Oncolytics
. 2023 Oct;
31:100728.
PMID: 37822488
Epidermal growth factor receptor (EGFR) is overexpressed in various cancers, including non-small cell lung cancer (NSCLC), and in some somatic cells at a limited level, rendering it an attractive antitumor...
3.
Characteristics of histamine H receptor agonist-induced allergic conjunctivitis model in Guinea pigs
Mochizuki H, Suyama S, Youm S, Ho P, Shimoi A
J Pharmacol Toxicol Methods
. 2022 Jul;
119:107203.
PMID: 35842185
Histamine is strongly associated with the onset of allergic conjunctivitis. The most recent cloned histamine H receptor antagonist is highly expected as a new therapeutic drug candidate. As a model...
4.
Mochizuki H, Suyama S, Cha J, Ho P, Shimoi A
J Pharmacol Toxicol Methods
. 2021 Nov;
113:107133.
PMID: 34798284
Allergic conjunctivitis is one of the most common immune diseases in the field of ophthalmology. The number of patients suffering from allergic conjunctivitis has been increasing, and there is still...
5.
Yagyu S, Mochizuki H, Yamashima K, Kubo H, Saito S, Tanaka M, et al.
Clin Transl Immunology
. 2021 Jun;
10(6):e1291.
PMID: 34123382
Objectives: Chimeric antigen receptor (CAR)-T cell therapy possesses the potential to cause unexpected on-target toxicities that may be life-threatening. Non-human primates (NHPs) share considerable structural homology and expression profiles of...
6.
Morokawa H, Yagyu S, Hasegawa A, Tanaka M, Saito S, Mochizuki H, et al.
Clin Transl Immunology
. 2020 Nov;
9(11):e1207.
PMID: 33251009
Objectives: Chimeric antigen receptor (CAR)-T cell therapy redirected to specific antigens on tumor cells is a promising immunotherapy strategy for various cancers. Most target antigens are also expressed on normal...
7.
Watanabe T, Yasuda S, Kusakawa S, Kuroda T, Futamura M, Ogawa M, et al.
Cytotherapy
. 2020 Sep;
23(2):176-183.
PMID: 32978066
Background Aims: The Multisite Evaluation Study on Analytical Methods for Non-Clinical Safety Assessment of Human-Derived Regenerative Medical Products (MEASURE) is a Japanese experimental public-private partnership initiative, which aims to standardize...
8.
Mochizuki H, Murota N, Sato S, Nii K, Kouhei Y, Taniguchi M, et al.
J Toxicol Sci
. 2018 Nov;
43(11):685-695.
PMID: 30405001
We investigated the viability of a combined repeated dose toxicity study, including toxicokinetics (TK), in common marmosets according to the ICH-S4, ICH-S3A and ICH-S7A Guidelines using valsartan as test article...
9.
Mochizuki H, Ohnuki Y, Kurosawa H
J Biosci Bioeng
. 2010 Sep;
111(1):92-7.
PMID: 20869914
Embryoid body (EB) formation is an important step in the differentiation of pluripotent stem cells. Although glucose concentration is physiologically maintained at 5.5mM (low glucose; LG) in vivo, a medium...